Abstract The purpose of this study was to explore the definition of fetal viability and the availability, indications, and decision making processes for post-viability termination of pregnancy for fetal abnormalities and health conditions in Canada. An online survey of members of the Canadian Association of Genetic Counsellors, the Canadian College of Medical Geneticists, and the Canadian Society for MaternalFetal Medicine who provide direct counselling to, or management of, prenatal patients in Canada (total sample size 815). Results of this study showed that the majority of respondents indicated that their centre will offer post-viability termination of pregnancy (98/123; 80 %). Sixty-seven percent (68/101) of respondents reported the definition of fetal viability to be 24 weeks' gestation. Most respondents reported that a collaborative decision making process was used to determine if postviability termination of pregnancy would be offered (136/170; 80 %). For conditions presumed to be lethal/likely lethal, the majority of respondents would Bsometimes^or Balways^offer post-viability termination of pregnancy, whereas for conditions presumed to have a mild effect, the majority of respondents would Brarely^or Bnever^offer post-viability termination of pregnancy. Ninety percent (77/86) of respondents reported that perinatal hospice is offered as an alternative to termination of pregnancy. In conclusion, this study suggests that although post-viability termination is available in many provinces in Canada, variation in the definition of fetal viability and indications appear to exist. While these variations may lead to unequal access to post-viability termination of pregnancy across Canada, they might also represent the complexity of the decision making process and the importance of examining individual factors to ensure that the most appropriate decision is made in each case.
Introduction
According to the Canada Health Act, abortion is a medically necessary procedure to be provided by provincial and territorial health insurance plans (Government of Canada 2011). There is no specific gestational age guideline. The Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Canadian Medical Association (CMA) affirm that induced abortion should be uniformly available to all women in Canada (Black et al. 2004; Canadian Medical Association 1988) . The CMA interprets induced abortion as Bthe active termination of a pregnancy before fetal viability^ (Canadian Medical Association 1988, PD88-06 . It is unknown if there is a generally accepted definition of fetal viability in Canada. In 2012, at least 80.4 % of induced abortions in Canada occurred at ≤20 weeks' gestation and at least 2.2 % occurred at ≥21 weeks' gestation. Seventeen percent of induced abortions were performed at an unknown gestational age (Canadian Institute for Health Information 2012).
The continuing evolution and availability of prenatal screening and diagnostic testing provides the opportunity to diagnose fetal abnormalities such as chromosomal aneuploidies, single gene conditions, and birth defects. While these diagnoses are often likely to be made prior to fetal viability, some diagnoses may be made close to or post-viability. Late diagnoses can pose challenges with regard to pregnancy management options as termination services after 20 weeks' gestation are not always readily accessible in all parts of Canada (Abortion Rights Coalition of Canada 2005). Significant variation exists across Canada regarding the availability and access to therapeutic abortion; for instance, Prince Edward Island has no abortion providers (Sabourin and Burnett 2012) . Furthermore, many barriers to obtaining this service have been described (Sabourin and Burnett 2012) . The Canadian Medical Association does state that elective termination of pregnancy after fetal viability may be indicated under exceptional circumstances; however, these circumstances do not appear to be specifically described (Canadian Medical Association 1988) .
Purpose of the Study
This survey study aims to assess the definition of fetal viability and the availability, indications, and decision making processes for post-viability termination of pregnancy for fetal abnormalities and health conditions in Canada.
Methods Sample
The sample population consisted of members of Canadian Association of Genetic Counsellors (n=320), the Canadian College of Medical Geneticists (n=350), and the Canadian Society for .
Instrumentation
A 26-item survey (online eAppendix) was developed using BSurveyMonkey.^Only an English version of the survey was produced. Questions were specifically designed to elicit responses to our study questions and were in the form of multiple choice and Likert scale with options to report alternate responses and associated explanations. There was some opportunity for open ended comments. The survey was divided into two sections: items for respondents whose centers will consider offering post-viability termination of pregnancy and items for respondents whose centers do not offer post-viability termination of pregnancy but who will consider referring elsewhere. General content areas of the survey included demographics, definitions of viability, decision making processes for offering post-viability termination of pregnancy, and general and specific fetal indications for offering or not offering post-viability termination of pregnancy.
Procedures
A study invitation containing the link to the survey was distributed between December 2012 and March 2013 to potential participants via their respective listservs. One reminder email was sent approximately 2 weeks' after the initial study invitation. Potential participants were informed of the purpose of the study through a letter of explanation. We addressed the potential concern regarding the controversial nature of the study topic and informed potential participants that responses would remain anonymous and confidential Participation was voluntary and participants could exit the survey at any time. Consent was implied by completion of the survey. Contact information for research members was provided to the participants. Upon completion of the survey, participants were given the option of providing their email address to be included in a drawing for a prize; this identifying information was not used in the analysis of responses. Inclusion criteria were being a health care professional and providing direct counselling to, or management of, prenatal patients in Canada.
Data Analysis
The survey responses were analyzed using calculated descriptive statistics.
Ethics approval (#6007500) for this study was granted by the Health Sciences Research Ethics Board at Queen's University.
Results
One-hundred sixty four respondents (164/815; 20 % initial response rate) started the survey, but 41 did not meet the inclusion criteria or completed only the first question of the survey and were therefore excluded. The total number of eligible respondents was 123/815; final response rate 15 %). Some respondents (17/123; 14 %) did not reply to every question.
Nine of the 13 provinces and territories were represented (Fig. 1) . Ontario had the highest representation (41/123; 33 %), followed by British Columbia (21/123; 17 %), Quebec (19/123; 15 %) , and Alberta (15/123; 12 %). Fortythree percent (53/123) of respondents were genetic counsellors, 39 % (48/123) were maternal-fetal medicine specialists, 15 % (18/123) were geneticists, 2 % (3/123) were nurse counsellors, and one individual (0.8 %) was a general obstetrician. The majority of respondents worked at a tertiary care center and/or a university associated center (109/123; 89 %); the remainder of respondents worked at a community hospital, private clinic, public health unit, or a combination of locations.
The majority of respondents indicated that their centre does offer post-viability termination of pregnancy (98/123; 80 %). Of those centres offering post-viability termination of pregnancy, the majority are tertiary care/university associated centres (131/140; 94 %), however, the data suggest that 14 % of respondents from tertiary care/university associated centres reported that their center does not offer post-viability TOP (18/131).
Definitions of fetal viability are shown in Fig. 2 . Respondents who chose Bother^reported a range of 23-24 weeks' gestation or explained that they have no clear definition of viability but use 24 weeks' gestation as a rough guideline. Responses from the majority of the provinces demonstrated two or more definitions of fetal viability, with the exceptions of Manitoba (24 weeks' gestation, 5/5 respondents), Saskatchewan (24 weeks' gestation, 5/5 respondents), and Newfoundland and Labrador (23 weeks' gestation, 1/1). The provinces with the majority of respondents reporting a definition of 24 weeks' gestation were British Columbia, Manitoba, New Brunswick, Ontario, Quebec, and Saskatchewan. The variation in definition does not appear to be related to facility type, as respondents from tertiary care, university associated, and community hospitals all provided a range of responses. Within each province, there is at least one centre/provider reporting a definition of fetal viability of 23 weeks' gestation.
Responses regarding how the decision is made to offer, or not offer, post-viability termination are shown in Table 1 .
Some respondents selected more than one option. Those selecting Bother^were prompted to comment. The majority of comments described a decision making approach that combined one or more of the options provided, a number of which specifically mentioned the involvement of an ethicist. Five respondents reported that a requirement of the decision making process was that the condition/findings are considered lethal. Four respondents reported that two physicians must be in agreement to provide post-viability termination of pregnancy. Three of the respondents who selected Bdefined protocol with no exceptions -written^also selected or commented that a review board is involved in the decision making process.
Respondents were asked to rate the involvement of various healthcare professionals using a Likert scale ranging from Balways^to Bnever.^Ninety-two percent (85/92) of respondents reported that Maternal-Fetal Medicine (MFM) specialists are Balways^involved in the decision making process. Health care professionals most commonly reported as Bsometimes^or Balwaysî nvolved included; geneticist (85/91; 94 %), appropriate specialist (e.g., neurology, cardiology, etc.) (80/88; 91 %), neonatology (77/89; 86 %), obstetrician (68/86; 79 %), genetic counsellor (64/83; 77 %), and an ethicist (59/86; 69 %). Responses regarding the involvement of a program manager were: 26 % (19/73) Balways,^23 % (17/73) Bsometimes,^16 % (12/73) Brarely,^22 % (16/ 73) Bnever,^and 12 % (9/73) Bunsure.^The most commonly selected answer for the involvement of spiritual care was Bsometimes^(30/76; 39 %), with the remainder of responses relatively evenly distributed among the (n=101) other options. Seven respondents also commented that nurses are involved in the decision making process, and two respondents reported involvement of social work. One respondent commented, BNon-MFMs will weigh in to help with prognosticating, but it is typically up to the discretion of two MFMs to ultimately offer the termination of pregnancy, or not, as they are the ones performing the procedure.F igure 3 shows responses regarding what respondents believe their center's most likely opinion regarding the acceptability of post-viability termination of pregnancy for general categories of abnormalities/conditions is and Fig. 4 shows responses regarding the acceptability of post-viability termination for specific indications at respondents' centres.
For the presumed lethal condition, thanatophoric dysplasia, four respondents (4/88; 5 %) reported that they would Brarelyĉ onsider offering post-viability termination for this condition, and four reported Bnever^(4/88; 5 %). However, 7/8 of these same respondents reported that they would Balways^offer post-viability termination for the presumed lethal conditions trisomy 13 and 18, with the eighth respondent reporting Bsometimes^for trisomy 13 and trisomy 18. For cases that have been deemed appropriate for postviability termination of pregnancy, the majority of respondents (84/89; 94 %) reported that their centre does not have an established upper gestational age limit for which postviability termination will be offered, and/or that each decision is made on a case-by-case basis. Three (3/89; 3 %) respondents confirmed their centre had an upper gestational age limit after which post-viability termination of pregnancy is not offered. When given the option to provide more information, one of these respondents reported a gestational limit of 26 weeks' for early induction of labour for non-lethal anomalies but no upper limit for induction of labour for lethal anomalies, while another respondent reported that lethal abnormalities or abnormalities associated with a Bseverely handicapped survivor^that are ascertained late will be offered induction of labour at any gestational age, but the earlier the better. Two percent (2/89) of respondents identified they were unsure. At discretion of the attending team 28
At discretion of a review board 27 Defined protocol with some case-by-case exceptions -written 24
Other 19 Defined protocol with some case-by-case exceptions -unwritten 11 Defined protocol with no exceptions -written 5
At discretion of a single physician 5 Defined protocol with no exceptions -unwritten 3
Unsure 2 *respondents were asked to select all that apply Respondents reported the involvement of genetic counselling prior to post-viability termination of pregnancy as follows: Balways^38 % (33/87), Bsometimes^48 % (42/87), Brarely^5 % (4/87), Bnever^6 % (5/87), and Bunsure^3 % (3/87). Respondents were asked if patients are required to attend counselling (other than genetic counselling) or undergo a psychological assessment prior to termination of pregnancy; the majority of respondents answered Bno^(60 %; 52/87), with 11 % (10/87) answering Byes^and 10 % (9/87) answering Bunsure.N inety percent (77/86) of respondents reported that perinatal hospice is offered as an alternative to termination of pregnancy. Seven percent (6/86) answered Bno,â nd 3 % (3/86) were Bunsure.^Figure 5 depicts the support that is offered to patients and families throughout the termination process.
Respondents were asked if pre-termination fetal injection with potassium chloride (KCl) is offered as part of the termination procedure. Fifty-two percent (45/86) reported Balways, 31 % (27/86) reported Bsometimes,^2 % (2/86) reported Brarely,^9 % (8/86) reported Bnever,^and 5 % (4/86) were Bunsure.F or cases where post-viability termination is ultimately deemed not appropriate at a respondent's centre, the majority of respondents (65/86; 76 %) would refer patients to the United States of America (USA). Twenty-three percent (20/ 86) would refer to another center outside their province/ territory and 21 % (18/86) would refer to another centre within their province/territory. Thirteen percent (11/86) of respondents reported that they do not refer their patients elsewhere for termination of pregnancy. Two percent (2/86) of respondents selected other and reported that they refer to Europe, and that they will inform their patients of options in the USA but will not refer directly.
Respondents were given the opportunity to provide openended thoughts/comments regarding this study and topic. Many respondents took this opportunity to explain nuances to their processes, further highlighting the case-specific nature of this decision. Respondents' comments revealed that the decision to offer or not offer post-viability termination of pregnancy is taken very seriously and highlighted the efforts of healthcare providers in trying to come to a decision that is in line with the families' wishes, professional opinions, and ethical guidelines.
Twenty percent (25/123) of respondents reported that their centre does not offer post-viability termination of pregnancy. These respondents represented centers in Alberta, British Columbia, Newfoundland and Labrador, Ontario, and Quebec. The majority of these respondents indicated that they worked in tertiary care and/or university associated and/or community hospitals. Of these respondents, the majority (17/26; 65 %) reported that they refer their patients to the USA. Twenty-three percent (6/26) refer to another centre within their province/territory, and 4 % (1/26) refer to another centre outside their province/territory. Seven percent (2/26) reported that they do not refer elsewhere. Table 2 shows respondents' answers regarding how the decision is made as to whether or not to refer a patient to another centre for consideration for post-viability termination. Of the respondents who selected Bother,^two provided comments. One explained they do not have a defined protocol, but it is generally accepted that any pregnancy with anomalies, a high risk of an abnormal outcome, or a genetic condition would be considered eligible for referral for consideration of termination. The other respondent commented that patient input is considered in the decision making process.
Discussion
Based on the results of this study, post-viability termination of pregnancy for fetal abnormalities/conditions appears to be available to some extent in all of the provinces/territories represented in this study. There were no respondents from the Northwest Territories, Yukon, Nunavut, or Prince Edward Island. According to Sabourin and Burnett (2012) , there are no abortion providers in Prince Edward Island (PEI), which can likely be extrapolated to also mean that post-viability termination of pregnancy is unlikely to be available in PEI. While post-viability termination of pregnancy appears to be available in many areas of Canada, the data suggest that there is variability in which centers will offer the procedure, the definition of fetal viability for the purpose of termination of pregnancy, and the indications for which post viability termination will be considered.
Although most tertiary care/university associated centers will offer post-viability termination of pregnancy, it appears from our study that some do not. Most centers not offering this service will refer their patients to another center either within the same province, to another province, or most commonly, to the United States. Therefore, the ease with which a patient can access this service may depend on their geographic location.
There is no single gestational age that is routinely used as a definition of fetal viability in Canada. In the Canadian paediatric community, a Bthreshold of viability^between 22 and 25 weeks' gestation appears to be a generally accepted approach, with survival being uncommon at 22 weeks' gestation and improved survival and neurodevelopmental outcome at 25 weeks' gestation with active treatment (Jefferies and Kirpalani 2012; Synnes et al. 2008) . The results of our study are reflective of this threshold of fetal viability, with respondents reporting a range of definitions of fetal viability for the purpose of termination of pregnancy, although the most commonly reported definition was 24 weeks' gestation. The variation in definition likely leads to women with the same or similar indication being offered termination of pregnancy at one center but denied at another. It could be suggested that the selection of a single definition of fetal viability for the purpose of termination of pregnancy would standardize one aspect of the complex decision to offer post-viability termination of pregnancy, thereby providing more equality in access to this service; however, this may not be feasible given the complex nature of fetal viability and varying professional opinions. From our study, it does seem that once a case has been deemed appropriate for post-viability termination of pregnancy, there is generally no strict upper limit for the gestational age at which the termination will be performed. Rather, it appears that each case is assessed individually to determine if post-viability Table 2 Responses regarding how the decision is made as to whether or not to refer patients to another center for consideration for postviability termination (n=23)
Answer options n
All case-by-case decisions 12
Other 3 Defined protocol with no exceptions -unwritten 2
Defined protocol with some case-by-case exceptions -written 2 At discretion of the attending team 2
Defined protocol with some case-by-case exceptions -unwritten 1
At discretion of a single physician 1 Unsure 1
Defined protocol with no exceptions -written 0 At discretion of a review board 0 *respondents were asked to select all that apply termination of pregnancy will be offered at the specific gestational age in question. With regard to the decision making process for offering termination of pregnancy, The Abortion Rights Coalition of Canada states that late-term abortion is a health procedure that should be left to the discretion of the doctor and patient and does not require political regulation (Abortion Rights Coalition of Canada 2005). To the best of our knowledge, there are no national Canadian guidelines regarding the decision making process for offering post-viability termination of pregnancy. In keeping with The Abortion Rights Coalition's position on late-term abortion, our study showed that nearly all of the respondents reported some form of discretion is used in the decision-making process to offer or not offer postviability termination of pregnancy. It appears that many centres do not use a defined decision making protocol, but rather, make the decision on either a case-by-case basis, at the discretion of the attending team, or at the discretion of a review board. For those who reported that their centre does have a defined protocol, the majority reported that some case-by-case exceptions are still made. Only a few respondents reported the decision is made by a single physician, demonstrating that this decision most commonly involves collaboration of a number of healthcare professionals, with the most commonly involved providers reported to be MFM specialists, geneticists, relevant specialists, neonatologists and ethicists.
Regarding indications for post-viability termination of pregnancy, The Canadian Medical Association suggests that elective termination of pregnancy after fetal viability may be indicated under exceptional circumstances, however, it does not provide any specific indications or framework for making this decision (Canadian Medical Association 1988). Our study suggests that presumed lethal/likely lethal conditions/ anomalies such as trisomy 13 and trisomy 18 will nearly always be considered an acceptable category for post-viability termination. However, there were a few respondents that indicated Bsometimes.^Interestingly, there were also a few respondents that reported they would rarely consider postviability termination for the presumed lethal condition thanatophoric dysplasia. These respondents' answers may represent a lack of familiarity with the presumed lethal nature of thanatophoric dysplasia and may not accurately represent their centres' decision to offer post-viability termination for this condition, reflecting a limitation of the survey design of the present study. Additionally, our study did not address postviability termination of pregnancy for maternal health reasons.
Women living in the majority of Canada's provinces/ territories have some access to ministry funded prenatal serum screening for Down syndrome (Hull et al. 2012) . Furthermore, the recent emergence of non-invasive prenatal testing (NIPT) using cell free fetal DNA to screen for Down syndrome with high accuracy will become increasingly available to women across Canada (Langlois et al. 2013) . Therefore, in combination with diagnostic procedures, Down syndrome can often be diagnosed prenatally and usually prior to fetal viability. However, for cases of Down syndrome that are diagnosed post-viability, our study suggests a notable variation in the availability of post-viability termination of pregnancy for Down syndrome; approximately 40 % of respondents indicated that post-viability termination of pregnancy is always or sometimes offered, while approximately 60 % of respondents indicated that it is rarely or never offered. Given that this is a relatively common screened and diagnosed condition in Canada, this discrepancy in offering post-viability termination of pregnancy is of particular significance and likely reflects numerous complex practitioner and center beliefs and policies. However, it also suggests inequality in the delivery of health care for women.
For categories and conditions expected to have an unknown or mild impact, such as an isolated cleft lip and/or palate, the responses trend toward not offering post-viability termination of pregnancy; however, some respondents did say they would offer termination of pregnancy for this indication. Similarly, for categories and conditions expected to have a more moderate or severe impact, such as Fragile X syndrome, the responses trend toward offering post-viability termination of pregnancy; however, there is wide variability in responses. These results suggest that the willingness to offer postviability termination of pregnancy appears to be directly related to the expected severity of the prognosis. The variation likely reflects differences in opinions of individual providers, but may also indicate difficulty in providing a standard response for complex scenarios given that each case is likely to have various factors to consider.
As expected, it appears that post-viability termination of pregnancy for childhood onset cancer syndromes, adult onset conditions with reduced penetrance, and adult onset conditions with 100 % penetrance is rarely or never offered. However, there were also many respondents who indicated that they were unsure. The decision to even offer prenatal diagnosis and pre-viability termination of pregnancy for these categories of conditions is layered with complexities and ethical challenges; we expect that the uncertainty of many respondents reflects the rare and challenging nature of this request. Although the decision to offer post-viability termination of pregnancy for these categories is rare, the issue may arise more frequently with increasing use of high resolution chromosomal microarray and exome sequencing in the prenatal setting.
The Society of Obstetricians and Gynaecologists of Canada (SOGC) recommends that every woman seeking abortion should receive supportive and compassionate counselling regarding all the options available, and must be assured of the availability of post-abortion counselling (Davis 2006) . Our study suggests that patients and families being considered for post-viability termination of pregnancy in Canada are nearly always offered support resources, including genetic counselling, social work consultation, support group information, bereavement information, and spiritual support consultation. Most patients are not required to participate in counselling services (other than genetic counselling) or undergo a psychological assessment. In addition, our study suggests that perinatal hospice, a comprehensive, compassionate model of care for patients and families who wish to continue their pregnancy following a diagnosis of a lethal or life limiting condition, is offered to the majority of patients as an alternative to termination of pregnancy (Hoeldtke and Calbourn 2001) . Nevertheless, it seems that this valuable alternative, which provides a balanced set of options, is still not uniformly available for patients. Finally, for those undergoing postviability termination of pregnancy, our study suggests that the majority of patients will always or sometimes be offered pre-termination KCl injection.
While the results of this study show that postviability termination of pregnancy is available in Canada, it also suggests that inequality in access to this service exists for reasons such as geographic location and variation in definitions of fetal viability and indications. This inequality implies that some women in Canada need to travel to another city, province, or country to be considered for post-viability termination of pregnancy whereas other women with the same indication could obtain this service close to their home. As previously described in the literature, the need to travel creates barriers to accessing this service (Sabourin and Burnett 2012; Sethna and Doull 2007) . Furthermore, guidelines regarding the definition of fetal viability for the purpose of termination of pregnancy, decision making processes, and appropriate indications might provide more equal care to women. However, the development of such guidelines might also hinder health care providers' ability to thoroughly assess each individual situation to make the best possible choice for each woman.
Study Limitations and Research Recommendations
This study has a number of limitations. The results of our survey only represent the opinions of providers who received the invitation to our study and those who chose to participate. Responses were not solicited from private abortion clinics. The variation in the number of respondents who answered each survey item further limits the ability to generalize the results. Our study does not include data from the Northwest Territories, Yukon, Prince Edward Island, or Nunavut. Data regarding the specific centre that respondents work at were not collected; therefore, it is unknown which centres were represented. Furthermore, respondents were allowed to select more than one centre type in which they work; therefore, for some respondents it is unknown which centre type their answers represent. In addition, there is no means to validate the answers to confirm data.
It is clear that a standard set of questions cannot fully ascertain what occurs in practice, as this is a very complex topic in which many factors must be considered. Future interview research could be useful in exploring the nuances in these complex decisions. Further study questions could explore if there is a perceived desire from healthcare providers and/or patients to create national guidelines on post-viability termination and how to address barriers that may limit equal access to post-viability termination.
Conclusion
Our findings suggest that post-viability termination of pregnancy will be considered under certain circumstances in all Canadian provinces/territories represented in this study. While the most commonly reported definition of fetal viability appears to be 24 weeks' gestation, variation does exist. The decision making process is reportedly quite similar; however, variation exists for some of the abnormalities/conditions for which the procedure will or will not be offered, particularly for Down syndrome. These variations likely lead to unequal access to post-viability termination of pregnancy for fetal abnormalities/conditions in Canada; however, the variation might also represent the complexity of the decision making process and differences in professional opinions. The results also suggest that the willingness to offer post-viability termination of pregnancy appears to be directly related to the expected severity of the prognosis. For cases deemed inappropriate for post-viability termination of pregnancy at a given location, it appears that the majority of women would be offered a referral to another centre in Canada or the USA for further consideration. While the existence of guidelines regarding fetal viability, indications, and decision-making processes for post-viability termination of pregnancy could assist with providing more uniform care to women in Canada, the existence of guidelines may also hinder providers from assessing the spectrum of factors that should be taken into account when making this complex decision.
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